Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a severe bleeding disorder which can result in intracranial haemorrhage (ICH), leading to death or neurological sequelae. In Caucasians, maternal anti-HPA-1a antibodies (abs) are responsible for the majority of FNAIT cases. However, the correlation between fetal platelet counts and risk of bleeding is loose. ICH was also observed in FNAIT cases with platelet counts within reference ranges. These observations question the exclusive role of thrombocytopenia in ICH. Recently, we observed stronger binding of anti-HPA-1a antibodies from mothers with ICH-positive (+ICH) FNAIT to endothelial cell-derived avb3 when compared to anti-HPA-1a from -ICH. Differential absorption experiments demonstrated that anti-HPA-1a is not a single antibody entity. Sera from immunized women may contain three different subspecificities: anti-b3, anti-aIIbb3 and anti-avb3. Anti-b3 appears to be the dominant subtype of anti-HPA-1a. However, anti-avb3 was only found in +ICH sera, and only the anti-avb3, but not anti-b3 subtype, induced apoptosis and disturbed tube formation of endothelial cells in vitro. Therefore, we believe that this anti-HPA-1a subtype plays a significant role in the development of ICH. Together with other subtypes, anti-avb3 may trigger bleeding in a threshold model of FNAIT/ ICH, where bleeding occurs if yet undefined levels of anti-endothelial (loss of integrity) and/or antiplatelet (low platelet count) activities are achieved. Thus, defining anti-HPA-1a subtypes may have significant potential in the prediction of ICH. With upcoming nation-wide screening programmes, detection of anti-HPA1a subtypes could prove helpful to allocate treatment to appropriate (at-risk) cases, especially in countries with restricted resources.
Introduction
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a bleeding disorder of the fetus and newborn in which maternal alloantibodies bind to the infant's platelets and cause their destruction during pregnancy and after birth. In Caucasians, approximately 80% of FNAIT cases are induced by antibodies against human platelet antigen 1a (HPA-1a) [1, 2] . Approximately 2000 out of 100 000 pregnancies occur in HPA-1a-negative women; 200 of these women will form anti-HPA-1a antibodies [3] . In~60 cases, the resulting fetal or neonatal thrombocytopenia will be severe (less than 50 G/l). The most devastating risk of Correspondence: Ulrich J. Sachs, Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Langhansstr. 7, 35392 Giessen, Germany E-mail: ulrich.sachs@med.uni-giessen. de FNAIT is intracranial haemorrhage (ICH), which will occur in approximately 6/200 cases. According to data analysed by Tiller and colleagues [4] , most of these intracranial bleeds occur prior to gestational week 28. The prognosis of ICH is very poor, with 33% mortality until day four and persistent neurological sequelae in more than 50% of surviving children. In addition, ICH will occur in a subsequent child of the same two parents with high probability. In a Dutch study [5] including 27 mothers with 62 pregnancies, the risk of recurrence was 79% (95% confidence interval, 61-97), and a literature-based analysis performed by Bussel and colleagues [6] calculated a very similar risk of 85% (95% confidence interval, 79-91). Although the recurrence rate of ICH is high and the clinical consequences are severe, it is currently unclear which factors determine whether ICH will occur.
Factors that may influence the natural cause of FNAIT
Numerous investigators have addressed the question which additional factors may influence the natural cause of the disease and, eventually, lead to ICH. It is beyond the scope of this paper to discuss these different findings in detail. However, all potential factors should fall within one of the following three categories: (1) the maternal immune response, that is quality or quantity of the anti-HPA-1a formed in the mother; (2) the fetal-maternal interface, that is placental function; and (3) intrafetal processes, that is presence of (immune) modulators in the fetus. In a literature review, we identified 11 factors that could in theory influence the natural cause of FNAIT (Table 1 ) and concluded that, based on current evidence, five of them should be considered possible candidates: antibodies which interfere with platelet function; antibodies with decreased Fc fucosylation which lead to increased platelet removal; high maternal antibody levels; increased platelet removal because of fetal inflammatory responses; and less as an underlying mechanism but more as a 'sum effect', the fetal/neonatal platelet count. However, none of these candidate mechanisms is a good predictor of ICH.
Off the platelet: the HPA-1a antigen is not platelet specific HPA-1a is formed by a single amino acid substitution (Leu 33 Pro) located on the flexible PSI domain of the integrin b3 chain [7] . On platelets, the b3 chain forms heterodimers with aIIb and functions as a (platelet-specific) fibrinogen receptor (often referred to as GPIIb/IIIa in platelet immunology) [8] . On platelets, b3 can also heterodimerize with the av chain to form a vitronectin receptor. In contrast to aIIbb3, the avb3 integrin is not only present on platelets, but also on numerous other cell types including, spermatozoa and the trophoblast [9] . Interestingly, it was demonstrated previously that avb3 is also constitutively expressed on endothelial cells (ECs) and that endothelial avb3 can bind anti-HPA-1a antibodies [10, 11] . The interaction between anti-HPA-1a and EC affects endothelial integrity and interferes with the spreading capability of these cells [12] . These intriguing findings could indicate that anti-HPA-1a antibodymediated vascular damage may be involved in the pathomechanism of FNAIT and contribute to intracranial bleeding. However, others have reported no effect of anti-HPA-1a antibodies on endothelial activation and/or integrity [13] , prompting us to consider that immune responses between mothers may differ with regard to the binding specificity of their anti-HPA-1a antibodies [14] .
Anti-HPA-1a antibodies from +ICH and -ICH cases bind differently to avb3
We performed an initial study with sera from HPA-1bb mothers who gave birth to children with FNAIT and ICH (+ICH) and sera from HPA-1bb mothers who gave birth to children with FNAIT, but without ICH (-ICH). The presence of anti-HPA-1a was confirmed by standard MAIPA, where platelet aIIbb3 is immobilized to the microtitre plate by the use of a confirmation-specific monoclonal antibody, Gi5 [15] . Apparently, no difference in binding was observed between the two cohorts (Fig. 1a) . The MAIPA was modified, and ECs instead of platelets were used. Integrin avb3 was immobilized by the use of a b3-specific monoclonal antibody (Fig. 1b) . A significant difference was observed between the +ICH and the -ICH cohort, indicating that +ICH anti-HPA-1a must contain additional antibody specificities not present in -ICH sera, most probably against avb3-'specific' (compound) epitopes. To generate further evidence for this hypothesis, we absorbed all sera with recombinant aIIbb3 and retested them in identical assays. As to be expected, reactivity with platelet-derived aIIbb3 in MAIPA was virtually lost after this absorption step (Fig. 1c) , with no difference between the cohorts. In contrast, as shown in Fig. 1d , 17 out of 18 + ICH sera remained reactive with EC-derived avb3 but none of the -ICH sera. We concluded from these serological studies that most +ICH sera contain anti-HPA-1a antibodies specific for compound epitopes present on avb3 [14] .
Only IgG from +ICH cases has functional effects on endothelial cells
Based on the fact that +ICH cases react predominantly with EC-derived avb3, we sought to investigate whether these antibodies would also interfere with EC function. It is well known in vascular biology that avb3-mediated adhesion to extracellular matrix is essential for EC growth and survival, whereas avb3 antagonism can induce endothelial apoptosis [16] . Experimental interference with avb3 ligation causes detachment-induced programmed cell death of EC via activation of the caspase-3 cascade [17, 18] . This programmed cell death is referred to as anoikis. In line with these observations, we could show that only the anti-avb3 subtype of anti-HPA-1a induced endothelial anoikis: binding of +ICH IgG (black) triggered endothelial apoptosis as measured by caspase-3/7 assay (Fig. 2) . IgG obtained from -ICH cases (white) did not induce EC apoptosis. The apoptosis rate induced by +ICH IgG remained unchanged after removal of the other subtypes by absorbing the patient sera with aIIbb3 (pre-vs.
postabsorption, P = 0Á106). Apparently, anti-HPA-1a antibodies specific for compound epitopes present on avb3 are capable of interfering with endothelial function and can induce programmed cell death [14] . Control experiments performed with HPA-1bb endothelial cells demonstrated that the effects were specifically dependent on the presence of the HPA-1a variant of the b3 chain.
Anti-HPA-1a can consist of three antibody subtypes, anti-aIIbb3, anti-avb3 and anti-b3, of which only anti-avb3 affects endothelial function line #1), human avb3 (cell line #2) or a chimeric aIIb(-mouse)b3(human) integrin (cell line #3) were generated. These cell lines were used to isolate the suspected different anti-HPA-1a antibody specificities by absorption/elution technique (Fig. 3a) , and antibodies from eluates (bound to the specific cell line; and then removed by acid elution) and absorbates (unbound; remaining in the supernatant after incubation with a specific cell line) were analysed in the apoptosis assay (Fig. 3b) . Analysis of eluates (Fig. 3b, upper panel) showed that only anti-HPA-1a antibodies with anti-avb3 specificity were able to induce apoptosis, indicating that anti-HPA-1a reactive with b3 alone is not able to induce endothelial apoptosis, neither by itself nor in combination with anti-aIIbb3. Analysis of absorbates (Fig. 3b, lower panel) showed that only anti-HPA-1a antibodies with anti-avb3 specificity can induce apoptosis (absorbate from #1 and #3) and that removal of this specificity by a cell line expressing avb3 (#3; compare upper and lower panel) abolishes this effect. In control experiments with HPA-1bb endothelial cells, none of the antibodies induced apoptosis (not shown). These results support our assumption that anti-HPA-1a antibodies reacting with the avb3 complex are responsible for the induction of apoptosis in EC.
How can anti-avb3 antibodies lead to intracranial bleeding?
Interference with avb3 ligation leads to anoikis, a process which impedes angiogenesis [19] [20] [21] . This well-described effect could be reproduced for +ICH sera in an endothelial tube formation assay: +ICH IgG (black), but not -ICH IgG (white), significantly reduced the length of endothelial tubes (Fig. 4) . Again, only the anti-avb3 subtype mediated the biological effect; removal of the other antibody subtypes by absorption had no influence on tube formation [14] . It has been reported that vessel development in the brain depends on crosstalk between EC and perivascular astrocytes [22] . For this process, av integrins play an important role through regulation of TGF-b activation and expression of TGF-b responsive genes that promote vessel differentiation and stabilization [23] [24] [25] . A critical period for ICH in FNAIT is before week 28 of gestation [4] . Of note, rapid development of premature medullary veins into shower-like numerous vessels associated with extensive angiogenesis has been observed between weeks 19 and 24 of gestation [26] . It is feasible to speculate that antibodies against avb3 interfere with these critical processes to provoke ICH, especially in the brain, within this period. Direct biological evidence other than from our association study is lacking. It is currently also unclear whether organ bleeding other than ICH (pulmonary, gastrointestinal, renal), which is only rarely reported in FNAIT, is also associated with anti-endothelial activity [27] .
Towards a serological assay to predict ICH
Once anti-HPA-1a of other subtypes has been removed from the serum, clinically relevant anti-HPA-1a of the anti-avb3 subtype can be demonstrated in an antigen capture assay (Fig. 1d) . Adjusting the current experimental assay to 100% specificity (no false-positive detection of anti-avb3 subtype in the -ICH cohort), 1/18 anti-HPA1a of the anti-avb3 subtype was not identified in the + ICH cohort, resulting in a negative predictive value of 94Á7% [14] . A routine assay for reliable diagnosis of the presence of anti-avb3 is currently under development.
Defining anti-HPA-1a subtypes in maternal serum may have significant potential in the diagnostic prediction of ICH development, and it may also allow for modification of prophylactic treatment. At the moment, we are unable to predict the outcome of a pregnancy in an immunized woman other than based on the outcome of her previous pregnancy: an ICH is very likely to re-occur if the woman is not treated (79-85% reoccurrence rate) [5, 6] . The risk for intracranial bleeding is low, but not inexistent, if a previous child was diagnosed with FNAIT, but no ICH. Antibody titres seem to be rather poor biomarkers for predicting ICH (Table 1) . Ideally, the absence of the anti-avb3 subtype indicates that no ICH will occur; women with a negative test result would then require no treatment. Of course, under real-world conditions, it seems unlikely that a single factor has such a strong predictive value. The authors currently believe that ICH mainly develops in fetuses with anti-HPA-1a antibodies of the anti-avb3 subtype and a low platelet count. We suggest that both mechanisms participate in overcoming an intracranial bleeding threshold, somewhat comparable to the Bux-Sachs threshold model of TRALI [28] . Accordingly, the FNAIT intracranial bleeding threshold can be exceeded in fetuses with only moderately reduced platelet counts, if the anti-endothelial activity is strong (Fig. 5, example A) . This example correlates with intracranial bleedings reported in FNAIT children with platelet counts >50 G/l; or even >100 G/l. Less antiendothelial activity is sufficient to overcome the threshold if the platelet count is low (Fig. 5, example B) . Whether ICH can even occur in the absence of antiavb3 antibodies remains to be determined. Obviously, both anti-endothelial activity and the platelet count might be modulated further by some of the factors mentioned in Table 1 such as inflammatory changes in the fetal organism.
Discussing anti-endothelial activity, as a side note, the fact that the av chain itself is also a polymorphic protein should not go unmentioned. We are unaware of studies demonstrating antigenicity for av amino acid exchanges, but av-dependent antibodies (possibly triggering ICH) would apparently remain undetected, even with AnƟ-HPA-1a anƟ-αIIbβ3, anƟ-α vβ3, and anƟ-β3 
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Very low Reduced Normal None Moderate Strong ICH threshold A B Fig. 5 FNAIT intracranial bleeding threshold model. This model suggests that a certain threshold must be overcome to induce intracranial bleeding in FNAIT. Overcoming the threshold depends on both, the antiendothelial activity of the anti-HPA-1a antibody (grey) and the platelet count (light). If the maternal antibody has strong anti-endothelial activity, ICH may occur even with only moderately reduced/near-normal fetal platelet counts (circle A). On the other hand, if the fetal platelet count is very low (circle B), moderate anti-endothelial activity will suffice to overcome the threshold. The model is adopted from the original TRALI threshold model from Bux & Sachs, 2007 [28] .
